Your search returned 3 results.

Results
	1.	Estimating the long-term cost-effectiveness of exenatide in the United States: an adjunctive treatment for type 2 diabetes mellitus. [electronic resource] by Minshall, Michael E Oglesby, Alan K Wintle, Matthew E Valentine, William J Roze, Stéphane Palmer, Andrew J Producer: 20080306 In: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research vol. 11 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	2.	Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials. [electronic resource] by Buse, John B Klonoff, David C Nielsen, Loretta L Guan, Xuesong Bowlus, Christopher L Holcombe, John H Maggs, David G Wintle, Matthew E Producer: 20070807 In: Clinical therapeutics vol. 29 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	3.	Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. [electronic resource] by Klonoff, David C Buse, John B Nielsen, Loretta L Guan, Xuesong Bowlus, Christopher L Holcombe, John H Wintle, Matthew E Maggs, David G Producer: 20080227 In: Current medical research and opinion vol. 24 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)